Arginase 2 deficiency results in spontaneous steatohepatitis: A novel link between innate immune activation and hepatic de novo lipogenesis

Journal of Hepatology

Volumn 62, Issue 2, 2015, Pages 412-420

  Navarro, Laura A ^a   Wree, Alexander ^b   Povero, Davide ^b   Berk, Michael P ^c   Eguchi, Akiko ^b   Ghosh, Sudakshina ^c   Papouchado, Bettina G ^d   Erzurum, Serpil C ^c   Feldstein, Ariel E ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arginase 2; Inflammation; Innate immunity; Liver fibrosis; Macrophage activation; Non alcoholic fatty liver disease; Steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; CLODRONIC ACID; LIPOSOME; MESSENGER RNA; ARG2 PROTEIN, MOUSE; ARGINASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARGINASE 2 DEFICIENCY; ARTICLE; CHEMICAL ANALYSIS; DISEASE COURSE; FAT INTAKE; FATTY LIVER; HEPATITIS; HYPERARGININEMIA; INNATE IMMUNITY; LIPID DIET; LIPOGENESIS; LIVER HISTOLOGY; LIVER INJURY; LIVER METABOLISM; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; COMPLICATION; DISEASE MODEL; IMMUNOBLOTTING; IMMUNOLOGY; KUPFFER CELL; LIPID METABOLISM; LIVER; METABOLISM; PATHOLOGY;

ANIMALS; ARGINASE; DISEASE MODELS, ANIMAL; FATTY LIVER; HYPERARGININEMIA; IMMUNITY, INNATE; IMMUNOBLOTTING; KUPFFER CELLS; LIPID METABOLISM; LIPOGENESIS; LIVER; MALE; MICE; MICE, INBRED C57BL;

EID: 84922219941     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.09.015     Document Type: Article

References (40)

1. Wieckowska A, Feldstein AE. Non-alcoholic fatty liver disease in the pediatric population: A review. Curr Opin Pediatr 2005; 17: 636-641.
2. Angulo P. Non-alcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
3. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004; 40: 1387-1395.
4. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118: 1388-1393.
5. Wieckowska A, Feldstein AE. Diagnosis of non-alcoholic fatty liver disease: Invasive versus noninvasive. Semin Liver Dis 2008; 28: 386-395.
6. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of non-alcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005; 129: 113-121.
7. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Non-alcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
8. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873.
9. Pascale A, Pais R, Ratziu V. An overview of non-alcoholic steatohepatitis: Past, present and future directions. J Gastrointest Liver Dis 2010; 19: 415-423.
10. Tilg H, Moschen AR. Evolution of inflammation in non-alcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-1846.
11. Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 2013; 10: 627-636.
12. Lewis JR, Mohanty SR. Non-alcoholic fatty liver disease: A review and update. Dig Dis Sci 2010; 55: 560-578.
13. Taylor BS, Alarcon LH, Billiar TR. Inducible nitric oxide synthase in the liver: Regulation and function. Biochem Biokhim 1998; 63: 766-781.
14. Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta 2011; 412: 1297-1305.
15. Fujita K, Nozaki Y, Yoneda M, Wada K, Takahashi H, Kirikoshi H, et al. Nitric oxide plays a crucial role in the development/progression of non-alcoholic steatohepatitis in the choline-deficient, l-amino acid-defined diet-fed rat model. Alcohol Clin Exp Res 2010; 34: S18-S24.
16. Aram G, Potter JJ, Liu X, Torbenson MS, Mezey E. Lack of inducible nitric oxide synthase leads to increased hepatic apoptosis and decreased fibrosis in mice after chronic carbon tetrachloride administration. Hepatology 2008; 47: 2051-2058.
17. Munder M. Arginase: An emerging key player in the mammalian immune system. Br J Pharmacol 2009; 158: 638-651.
18. Gotoh T, Sonoki T, Nagasaki A, Terada K, Takiguchi M, Mori M. Molecular cloning of cDNA for nonhepatic mitochondrial arginase (arginase II) and comparison of its induction with nitric oxide synthase in a murine macrophage-like cell line. FEBS Lett 1996; 395: 119-122.
19. Jenkinson CP, Grody WW, Cederbaum SD. Comparative properties of arginases. Comp Biochem Physiol B Biochem Mol Biol 1996; 114: 107-132.
20. Mori M. Regulation of nitric oxide synthesis and apoptosis by arginase and arginine recycling. J Nutr 2007; 137: 1616S-1620S.
21. Gallardo-Soler A, Gomez-Nieto C, Campo ML, Marathe C, Tontonoz P, Castrillo A, et al. Arginase I induction by modified lipoproteins in macrophages: A peroxisome proliferator-activated receptor-gamma/delta-mediated effect that links lipid metabolism and immunity. Mol Endocrinol 2008; 22: 1394-1402.
22. Louis CA, Reichner JS, Henry Jr WL, Mastrofrancesco B, Gotoh T, Mori M, et al. Distinct arginase isoforms expressed in primary and transformed macrophages: Regulation by oxygen tension. Am J Physiol 1998; 274: R775-R782.
23. Salimuddin, Nagasaki A, Gotoh T, Isobe H, Mori M. Regulation of the genes for arginase isoforms and related enzymes in mouse macrophages by lipopolysaccharide. Am J Physiol 1999; 277: E110-E117.
24. Shi O, Morris Jr SM, Zoghbi H, Porter CW, O'Brien WE. Generation of a mouse model for arginase II deficiency by targeted disruption of the arginase II gene. Mol Cell Biol 2001; 21: 811-813.
25. Alkhouri N, Gornicka A, Berk MP, Thapaliya S, Dixon LJ, Kashyap S, et al. Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis. J Biol Chem 2010; 285: 3428-3438.
26. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
27. Wree A, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay A, et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology 2014; 59: 898-910.
28. van Rooijen N, Hendrikx E. Liposomes for specific depletion of macrophages from organs and tissues. Methods Mol Biol 2010; 605: 189-203.
29. van Rooijen N, Sanders A, van den Berg TK. Apoptosis of macrophages induced by liposome-mediated intracellular delivery of clodronate and propamidine. J Immunol Methods 1996; 193: 93-99.
30. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: The emerging view. J Hepatol 2009; 51: 212-223.
31. Thuy S, Ladurner R, Volynets V, Wagner S, Strahl S, Konigsrainer A, et al. Non-alcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008; 138: 1452-1455.
32. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 1997; 94: 2557-2562.
33. Mathurin P, Deng QG, Keshavarzian A, Choudhary S, Holmes EW, Tsukamoto H. Exacerbation of alcoholic liver injury by enteral endotoxin in rats. Hepatology 2000; 32: 1008-1017.
34. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887.
35. Vanni E, Bugianesi E. The gut-liver axis in non-alcoholic fatty liver disease: Another pathway to insulin resistance? Hepatology 2009; 49: 1790-1792.
36. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004; 101: 15718-15723.
37. Fabbrini E, Sullivan S, Klein S. Obesity and non-alcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology 2010; 51: 679-689.
38. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with non-alcoholic Fatty liver disease. Gastroenterology 2014; 146: 726-735.
39. Ferre P, Foufelle F. Hepatic steatosis: A role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 2010; 12: 83-92.
40. Shiri-Sverdlov R, Wouters K, van Gorp PJ, Gijbels MJ, Noel B, Buffat L, et al. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J Hepatol 2006; 44: 732-741.